Bibliography
- Williams AR, Trachtenberg B, Velazquez DL, Intramyocardial stem cell injection in patients with ischemic cardiomyopathy: functional recovery and reverse remodeling. Circ Res 2011;108(7):792-6
- Kinkaid HY, Huang XP, Li RK, Weisel RD. What's new in cardiac cell therapy? Allogeneic bone marrow stromal cells as “universal donor cells”. J Card Surg 2010;25:359-66
- Chin SP, Poey AC, Wong CY, Intramyocardial and intracoronary autologous bone marrow derived mesenchymal stromal cell treatment in chronic severe dilated cardiomyopathy. Cytotherapy 2011;13(7):814-21
- Zhuo Y, Li SH, Chen MS, Aging impairs the angiogenic response to ischemic injury and the activity of implanted cells: combined consequences for cell therapy in older recipients. J Thorac Cardiovasc Surg 2010;139(5):1286-94
- Nauta AJ, Fibbe WE. Immunomodulatory properties of mesenchymal stromal cells. Blood 2007;110(10):3499-506
- Atoui R, Shum-Tim D, Chiu RCJ. Myocardial regenerative therapy: immunologic basis for the potential “universal donor cells”. Ann Thorac Surg 2008;86:327-34
- Aggarwal S, Pittenger M. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005;105:1815-22
- Kassis I, Vaknin-Dembinsky A, Karussis D. Bone marrow mesenchymal stem cells: agents of immunomodulation and neuroprotection. Curr Stem Cell Res Ther 2011;6(1):63-8
- Nauta AJ, Westerbuis G, Kruisselbrink AB, Donor-dereived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting. Blood 2006;108(6):2114-20
- Spaggiari GM, Capobianco A, Becchetti S, Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2 induced NK-cell proliferation. Blood 2006;107(4):1484-90
- Al Kindi AH, Asenjo JF, Ge Y, Microencapsulation to reduce mechanical loss of microspheres: implications in myocardial cell therapy. Eur J Cardiothorac Surg 2011;39(2):241-7
- Bartholomew A, Sturgeon C, Satskas M, . Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 2002;30:42-8
- Saito T, Kuang JQ, Bittira B, Xenotransplant cardiac chimera: immune tolerance of adult stem cells. Ann Thorac Surg 2002;74:19-24
- Liechty KW, Mackenzie TC, Shaaban AF, Human mesenchymal stem cells engraft and demonstrate site-specific differentiation after in utero transplantation in sheep. Nat Med 2000;11:1282-6
- MacDonald D, Saito T, Shum-Tim D, Persistence of marrow stromal cells implanted into acutely infarcted myocardium: observations in a xenotransplant model. J Thorac Cardiovasc Surg 2005;130:1114-21
- Atoui R, Asenjo JF, Duong M, Marrow stomal cells as “universal donor cells” for myocardial regenerative therapy: their unique immune tolerance. Ann Thorac Surg 2008;85:571-80
- Grinnemo K, Mansson A, Dellgren D, Xenoreactivity and engraftment of human mesenchymal stem cells transplanted into infracted rat myocardium. J Thorac Cardiovasc Surg 2004;127:1293-300
- Prasad VK, Lucas KG, Kleiner GI, Efficacy and safety of ex vivo cultured adult human mesenchymal stem cells (Prochymal) in pediatric patients with severe refractory acute graft-versus-host disease in a compassionate use study. Biol Blood Marrow Transplant 2011;17(4):531-41
- Trachtenberg B, Velazquez DL, Williams AR, Rationale and design of the transendocardial injection of autologous human cells (bone marrow or mesenchymal) in chronic ischemic left ventricular dysfunction and heart failure secondary to myocardial infarction (tac-hft) trial: a randomized, double-blind, placebo-controlled study of safety and efficacy. Am Heart J 2011;161(3):487-93
- Breitbach M, Bostani T, Roell W, Potential risks of bone marrow cell transplantation into infarcted hearts. Blood 2007;110(4):1362-9